Key Takeaways
- Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a gene therapy treating severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
- Shares of RCKT surged up to 9% during premarket hours on Friday, ultimately closing approximately 6% higher.
- This marks the first FDA-cleared gene therapy specifically designed for severe LAD-I, a life-threatening immune disorder affecting children.
- The FDA granted Rocket a valuable Rare Pediatric Disease Priority Review Voucher, which the biotech intends to sell.
- The green light followed a resubmission after the FDA declined the application in June 2024, requesting additional supporting data.
Rocket Pharmaceuticals saw its stock price climb as much as 9% in early Friday trading after the FDA granted approval for its gene therapy KRESLADI, with shares stabilizing around 6% gains at the opening bell.
Rocket Pharmaceuticals, Inc., RCKT
The regulatory green light came through the accelerated pathway, which relies on preliminary clinical evidence—in this case, elevated neutrophil CD18 and CD11a surface expression levels. Complete verification of therapeutic benefits will require extended data collection from an active trial and a post-approval registry.
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The treatment is authorized for children diagnosed with severe LAD-I resulting from biallelic variants in the ITGB2 gene, specifically those without access to an HLA-matched sibling donor for stem cell transplantation.
LAD-I constitutes an extremely rare genetic immune deficiency disorder. The condition triggers repeated infections and presents significant mortality risk during early childhood when left untreated. Within the United States, occurrence rates are approximated at one case per 100,000 to 200,000 live births, with severe cases comprising roughly two-thirds of all diagnoses.
KRESLADI now stands as the inaugural FDA-approved gene therapy addressing this particular condition.
The path to approval encountered obstacles along the way. In June 2024, the FDA turned down the biologics license application, requesting that Rocket furnish supplementary data before finalizing its assessment.
Rocket resubmitted its BLA, which the FDA accepted in October 2024, establishing March 28, 2026 as the goal action date—a timeline the regulatory body successfully honored.
Priority Review Voucher Provides Financial Boost
Beyond the approval itself, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. These certificates can be transferred to other pharmaceutical companies for valuations reaching hundreds of millions of dollars and represent a substantial financial benefit accompanying the approval.
Rocket indicated its intention to explore monetization strategies for the voucher to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Scientific Foundation Behind the Therapy
The research underpinning KRESLADI’s creation received partial funding from the California Institute for Regenerative Medicine. The therapeutic agent focuses on the ITGB2 gene, which produces a protein critical for enabling white blood cells to combat infections.
The Cranbury, New Jersey-headquartered biotechnology firm has pursued this approval over multiple years.
The FDA’s designated action date for the resubmitted BLA was March 28, 2026, with the agency delivering approval precisely as scheduled.
